Article
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
Nature medicine - 1 May 2022
Chandran Smita S, Ma Jiaqi, Klatt Martin G, Dündar Friederike, Bandlamudi Chaitanya, Razavi Pedram, Wen Hannah Y, Weigelt Britta, Zumbo Paul, Fu Si Ning, Banks Lauren B, Yi Fei, Vercher Enric, Etxeberria Inaki, Bestman Watchain D, Da Cruz Paula Arnaud, Aricescu Ilinca S, Drilon Alexander, Betel Doron, Scheinberg David A, Baker Brian M, Klebanoff Christopher A
Abstract excerpt
Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes derived from recurrently mutated driver genes. Here we describe a high-throughput platform combining single-cell transcriptomic and T cell receptor (TCR) sequencing to establish whether mutant PIK3CA, among the most frequently genomically altered driver oncogenes, generates an immunogenic public NeoAg. Using this strategy, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.